News By Tag
* anti-infectives Antimicrobial
* More Tags...
News By Location
Michael G. Kurilla of NIH to present at Anti-infectives Partnering meeting Nov 7-8, 2011, Boston
Michael G. Kurilla, Director of the Office of BioDefense Research Affairs at NIAID, NIH will give a featured presentation at the 8th Anti-infectives Partnering and Deal-making Conference (Nov 7-8, 2011 in Boston, MA)
Traditional antiviral drug discovery and development have typically focused on targets that are mostly virus specific or at most potentially applicable to a single family. Due to the limited genetic potential of viral genomes, “druggable”
Dr. Kurilla is the Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID). His primary role is to provide overall institute coordination for product development of medical countermeasures against bioterror threats. At the University of Virginia, he was an Assistant Professor of Pathology as well as Co-Director of the Laboratory of Molecular Diagnostics and Associate Director for Clinical Microbiology. He moved to the private sector working in anti-infective drug development at Dupont Pharmaceuticals, Bristol-Myers Squibb, and Wyeth. He subsequently joined the National Institute of Allergy and Infectious Diseases (NIAID) as a Medical Officer.
The 8th Anti-infectives Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the infectious diseases industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant infectious disease issues and partnerships that will affect the industry.
The conference is part of the Infectious Diseases World Summit, which consists of 2 tracks including the 9th Vaccines Discovery and Development:
For more information, please visit www.gtcbio.com